All patients with GPP benefit from IL-36 inhibitor therapy

Trial

Phase 2, Effisayil 1

Conference

SPIN 2022

26 August, 2022 10:37

IL-36 gene expression in GPP lesions reduced by spesolimab

Presented By

Dr Ahmed Farag

Conference

PFGC 2021

2 February, 2022 15:09

Presented By

Dr Rachel Giles, Medicom

Conference

PFGC 2021

22 December, 2021 08:12

Presented By

Prof. Hervé Bachelez, Hôpital Saint-Louis, France

Trial

Phase 2, Effisayil 1

Conference

WPPAC 2021

17 September, 2021 11:04